---
reference_id: "PMID:38907189"
title: Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels.
authors:
- Pardo J
- Capdevila-Lacasa C
- Segura B
- Pané A
- Montserrat C
- de Talló Forga-Visa M
- Moreno PJ
- Garrabou G
- Grau-Junyent JM
- Junqué C
- Consortium PKU.cat.
journal: J Neurodev Disord
year: '2024'
doi: 10.1186/s11689-024-09553-w
content_type: abstract_only
---

# Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels.
**Authors:** Pardo J, Capdevila-Lacasa C, Segura B, Pané A, Montserrat C, de Talló Forga-Visa M, Moreno PJ, Garrabou G, Grau-Junyent JM, Junqué C, Consortium PKU.cat.
**Journal:** J Neurodev Disord (2024)
**DOI:** [10.1186/s11689-024-09553-w](https://doi.org/10.1186/s11689-024-09553-w)

## Content

1. J Neurodev Disord. 2024 Jun 21;16(1):33. doi: 10.1186/s11689-024-09553-w.

Volumetric brain reductions in adult patients with phenylketonuria and their 
relationship with blood phenylalanine levels.

Pardo J(1)(2), Capdevila-Lacasa C(1)(2), Segura B(3)(4)(5), Pané A(6)(7), 
Montserrat C(7), de Talló Forga-Visa M(7), Moreno PJ(8)(9)(10), Garrabou 
G(8)(9)(10), Grau-Junyent JM(8)(9)(10), Junqué C(1)(2)(11); Consortium PKU.cat..

Collaborators: Argudo-Ramírez A, Barrau-Martínez B, Cantó J, Campistol J, 
Cardellach F, Casals-Pascual C, Chiva-Blanch G, García-Arenas D, García-García 
FJ, García-Villoria J, González de Aledo-Castillo JM, González-Rodríguez A, 
Guitart-Mampel M, Isern P, Jiménez A, Laudo B, Llorach R, Andújar-Sánchez F, 
López-Galera R, Meavilla SM, Milisenda JC, Morales B, Moreno-Lozano PJ, Moreno 
J, Nos M, Ormazabal A, Ortega Ferrer M, Ortega E, Padrosa J, Paredes AJ, Rubio 
E, Tobías E, Torremade J, Urpi-Sarda M, Valls L, Ventura R, Vergara-Gómez A, 
Viaplana J, Viñals C.

Author information:
(1)Institute of Neurosciences, Medical Psychology Unit, Department of Medicine, 
University of Barcelona, C/ Casanova 143, Barcelona, Catalonia, 08036, Spain.
(2)Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques 
August Pi I Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.
(3)Institute of Neurosciences, Medical Psychology Unit, Department of Medicine, 
University of Barcelona, C/ Casanova 143, Barcelona, Catalonia, 08036, Spain. 
bsegura@ub.edu.
(4)Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques 
August Pi I Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain. bsegura@ub.edu.
(5)Biomedical Research Networking Center On Neurodegenerative Diseases 
(CIBERNED: CB06/05/0018-ISCIII), Barcelona, Catalonia, Spain. bsegura@ub.edu.
(6)Biomedical Research Networking Center on Physiopathology of Obesity and 
Nutrition (CIBEROBN), Barcelona, Catalonia, Spain.
(7)Endocrinology and Nutrition Department, Adult Inherited Metabolic Disorders 
Unit (UECMA), Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
(8)Internal Medicine Department, Adult Inherited Metabolic Disorders Unit 
(UECMA), Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
(9)Inherited Metabolic Diseases and Muscle Disorders Research, Centre de Recerca 
Biomèdica CELLEX - Institut d'Investigacions Biomèdiques August Pi i Sunyer 
(IDIBAPS) and Faculty of Medicine and Health Sciences, University of Barcelona, 
Barcelona, Catalonia, Spain.
(10)Biomedical Research Networking Center on Rare Diseases (CIBERER), Barcelona, 
Catalonia, Spain.
(11)Biomedical Research Networking Center On Neurodegenerative Diseases 
(CIBERNED: CB06/05/0018-ISCIII), Barcelona, Catalonia, Spain.

BACKGROUND: Continued dietary treatment since early diagnosis through newborn 
screening programs usually prevents brain-related complications in 
phenylketonuria (PKU). However, subtle neurocognitive and brain alterations may 
be observed in some adult patients despite early treatment. Nevertheless, 
neuropsychological and neuroimaging studies in the field remain scarce.
OBJECTIVES: This work aimed to determine possible neuropsychological and 
structural brain alterations in treated adult patients with PKU.
METHODS: Thirty-five patients with PKU and 22 healthy controls (HC) underwent 
neuropsychological assessment and T1-weighted magnetic resonance imaging on a 
3 T scanner. FreeSurfer (v.7.1) was used to obtain volumetric measures and SPSS 
(v27.0.1.0) was used to analyze sociodemographic, neuropsychological, 
volumetric, and clinical data (p < 0.05).
RESULTS: Adult patients with PKU showed significantly lower performance than HC 
in Full Scale IQ (t = 2.67; p = .010) from the WAIS-IV. The PKU group also 
showed significantly lower volumes than HC in the pallidum (U = 224.000; 
p = .008), hippocampus (U = 243.000; p = .020), amygdala (U = 200.000; 
p = .002), and brainstem (t = 3.17; p = .006) as well as in total cerebral white 
matter volume (U = 175.000; p = .001). Blood phenylalanine (Phe) levels in PKU 
patients were negatively correlated with the pallidum (r = -0.417; p = .013) and 
brainstem (r = -0.455, p = .006) volumes.
CONCLUSIONS: Adult patients with early-treated PKU showed significantly lower 
global intelligence than HC. Moreover, these patients showed reduced global 
white matter volume as well as reductions in the volume of several subcortical 
grey matter structures, which might be related to the existence of underlying 
neurodevelopmental alterations. Higher blood Phe levels were also negatively 
correlated with pallidum and brainstem, suggesting a higher vulnerability of 
these structures to Phe toxicity.

© 2024. The Author(s).

DOI: 10.1186/s11689-024-09553-w
PMCID: PMC11193301
PMID: 38907189 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no competing interests.